Francisco Talavera, PharmD, PhD, obtained his doctorate in science from Washington State University and pursued a postdoctoral fellowship in endocrinology and cancer research at the University of Michigan under a National Research Award from the National Cancer institute. He has published 17 studies in peer-reviewed journals. He then went on to earn his Doctor of Pharmacy degree from Creighton University. For the past 26 years he has worked as a managing editor for the Drug Reference at Medscape.
Recent WebMD content from Francisco Talavera, PharmD, PhD
- FDA Approves Palsonify: First Once-Daily Pill for Acromegaly in Adults
- Inluriyo: FDA Approves New Once-Daily Pill for ESR1-Mutated Advanced Breast Cancer in Patients Previously on Hormone Therapy
- Tremfya: First Fully Under-the-Skin IL-23 Inhibitor Shot Approved for Ulcerative Colitis and Crohn’s Disease
- Keytruda Qlex: FDA Approves New Subcutaneous Immune Therapy Shot for Treating a Wide Range of Advanced Cancers
- Forzinity: New Once-Daily Shot Gets Accelerated FDA Nod for Boosting Muscle Strength in Barth Syndrome
- FDA Approves At-Home Once-Weekly Leqembi Injection as Maintenance Therapy for Early Alzheimer's Disease
- Papzimeos: First Approved Immunotherapy for Recurrent Respiratory Papillomatosis in Adults
- Brinsupri: First Once-Daily Tablet for Non-Cystic Fibrosis Bronchiectasis
- Hernexeos (Zongertinib) Approved as the First Oral Targeted Treatment for HER2-Mutant Advanced Lung Cancer